Origin & tradition
Not a supplement: semaglutide is a prescription GLP-1 receptor agonist, FDA-approved for type 2 diabetes (Ozempic/Rybelsus) and chronic weight management (Wegovy).
Western tradition · GLP-1 agonist · prescription
Semaglutide (GLP-1 Agonist) 司美格鲁肽（GLP-1受体激动剂）
An FDA-approved diabetes/obesity drug backed by a genuinely strong cardiovascular-outcomes trial (SELECT) — its 'anti-aging' framing rests on small, early biomarker studies (epigenetic clocks, telomeres) that do not yet establish a longevity effect.
9ClinicalTrials.gov matched
19PubMed RCT records
8Meta-analysis records
16+PubMed records
SemaglutideKey active compound
Data definition. Matched records include all indexed medical endpoints for this intervention — not only longevity. Longevity-relevant records are screened separately and cited in the evidence summary below. Counts are matched-record volumes, not de-duplicated trials and not efficacy claims.
Why longevity buyers care
Key active: Semaglutide (GLP-1 receptor agonist).
Semaglutide mimics the gut hormone GLP-1, improving glycemic control and driving significant weight loss; the SELECT trial — a large, hard-outcomes RCT — showed a 20% reduction in major cardiovascular events in adults with overweight/obesity and existing cardiovascular disease, independent of diabetes status. Newer, smaller studies report reduced inflammatory markers, favorable shifts on epigenetic-aging clocks, and improved liver histology (ESSENCE trial), and animal work shows reduced cellular-senescence markers — but these are early, mechanism-level or small-pilot findings, not evidence that semaglutide extends human lifespan or healthspan beyond its established metabolic/cardiovascular benefits. Lean-mass loss alongside fat loss is a well-documented trade-off requiring resistance training and adequate protein.
Effect summary
Studied health outcomes
Editorial summary — This table is curated by hand from published research consensus, not automatically calculated from our trial database. Grades reflect our interpretation of the literature. Treat as a starting point, not a definitive verdict. See the Evidence panel below for the underlying trial and paper counts sourced directly from ClinicalTrials.gov and PubMed.
| Health outcome | Effect | Magnitude | Grade |
|---|---|---|---|
| Body weight | Decreases | Strong | A |
| Major adverse cardiovascular events (SELECT trial, overweight/obese with CVD) | Decreases | Moderate | A |
| HbA1c / glycemic control | Decreases | Strong | A |
| Lean muscle mass — Documented alongside fat loss; mitigated by resistance training and adequate protein intake | Decreases | Moderate | B |
| Epigenetic aging clocks / cellular senescence markers — Early, small pilot studies — not yet an established longevity effect | Decreases | Minor | C |
| Human lifespan extension — No trial designed or powered to test this | No change | Negligible | D |
Grade: A = robust RCTs · B = several RCTs / meta-analysis · C = limited or mixed RCTs · D = observational or early data
Dosage guidance
How Semaglutide (GLP-1 Agonist) is typically used
Prescription medication — requires a licensed prescriber. Not a supplement.
- Typical dose
- Titrated from 0.25 mg up to 1–2.4 mg/week (weight-management dosing; diabetes dosing differs)
- Form
- prescription only — subcutaneous injection (weekly) or oral tablet (Rybelsus, daily)
- Timing
- once weekly (injection) or once daily (oral), per prescribing physician; dose titrated slowly to manage GI side effects
PRESCRIPTION ONLY. FDA-approved for type 2 diabetes and chronic weight management — not for general anti-aging use. Common side effects: nausea, GI upset. Requires resistance training and adequate protein to offset lean-mass loss. Discontinuation is typically followed by substantial weight regain unless lifestyle changes are sustained.
Informational only — not a prescription or personalised medical advice. Consult a qualified clinician before starting any supplement or medication.
Evidence summary
What the research actually says
56Evidence confidence
Human RCT evidence19 randomized controlled trials · 8 meta-analyses / systematic reviews
Large hard-outcomes RCT (SELECT) for cardiovascular events; longevity/aging-biomarker evidence is early and small-scale
Semaglutide mimics the gut hormone GLP-1, improving glycemic control and driving significant weight loss; the SELECT trial — a large, hard-outcomes RCT — showed a 20% reduction in major cardiovascular events in adults with overweight/obesity and existing cardiovascular disease, independent of diabetes status. Newer, smaller studies report reduced inflammatory markers, favorable shifts on epigenetic-aging clocks, and improved liver histology (ESSENCE trial), and animal work shows reduced cellular-senescence markers — but these are early, mechanism-level or small-pilot findings, not evidence that semaglutide extends human lifespan or healthspan beyond its established metabolic/cardiovascular benefits. Lean-mass loss alongside fat loss is a well-documented trade-off requiring resistance training and adequate protein.
9registered clinical trials reference this intervention
3selected from 16+ PubMed papers (longevity / aging angle)
Key active: Semaglutide (GLP-1 receptor agonist).
According to PubMed and ClinicalTrials.gov: trial counts from ClinicalTrials.gov, peer-reviewed literature from PubMed. Counts auto-refresh weekly; last checked 2026-07-19. They include trials across many endpoints, not only longevity.
Informational only — not medical advice, a treatment claim, or a substitute for a qualified clinician. Evidence strength varies; we show mixed and null results on purpose.
Evidence collections
Semaglutide (GLP-1 Agonist) appears in
Suppliers
No Semaglutide (GLP-1 Agonist) suppliers listed yet
Tell us what you need and we will source suppliers for you.